Antibody-conjugated, dual-modal, near-infrared fluorescent iron oxide nanoparticles for antiamyloidgenic activity and specific detection of amyloid-β fibrils

International Journal of Nanomedicine

Volumn 8, Issue , 2013, Pages 4063-4076

  Skaat, Hadas ^a   Corem Slakmon, Enav ^a   Grinberg, Igor ^a   Last, David ^b   Goez, David ^b   Mardor, Yael ^b,c   Margel, Shlomo ^a  

^a BAR ILAN UNIVERSITY   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

Amyloid Peptide; Near infrared fluorescent Fe2O3 nanoparticles; Neurodegenerative diseases; Passive immunotherapy; Protein folding

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; AMYLOID BETA PROTEIN[1-40]; FERRIC OXIDE; MONOCLONAL ANTIBODY; NANOPARTICLE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL VIABILITY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; FLUORESCENCE IMAGING; IMMUNOGOLD LABELING; MALE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHEOCHROMOCYTOMA CELL; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN ANALYSIS; PROTEIN CROSS LINKING; PROTEIN IMMOBILIZATION;

AMYLOID-Β PEPTIDE; NEAR-INFRARED FLUORESCENT Γ-FE2O3 NANOPARTICLES; NEURODEGENERATIVE DISEASES; PASSIVE IMMUNOTHERAPY; PROTEIN FOLDING;

AMYLOID; AMYLOIDOSIS; ANIMALS; ANTIBODIES, MONOCLONAL; INFRARED RAYS; MAGNETITE NANOPARTICLES; MALE; MICROSCOPY, FLUORESCENCE; MOLECULAR IMAGING; RATS, SPRAGUE-DAWLEY; TREATMENT OUTCOME;

EID: 84886845276     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S52833     Document Type: Article

References (65)

1. Jellinger KA. Interaction between pathogenic proteins in neurodegenerative disorders. J Cell Mol Med. 2012;16(6):1166-1183.
2. Moreno-Gonzalez I, Soto C. Misfolded protein aggregates: mechanisms, structures and potential for disease transmission. Semin Cell Dev Biol. 2011;22(5):482-487.
3. Chiti F, Dobson CM. Protein misfolding, functional amyloid, and human disease. Annu Rev Biochem. 2007;5:333-366.
4. Kumar S, Udgaonkar JB. Mechanisms of amyloid fibril formation by proteins. Curr Sci. 2010;98:639-656.
5. Marshall KE, Serpell LC. Insights into the structure of amyloid fibrils. Open Biol J. 2009;2:185-192.
6. Roychaudhuri R, Yang M, Hoshi MM, Teplow DB. Amyloid beta-protein assembly and Alzheimer disease. J Biol Chem. 2009;284(8): 4749-4753.
7. Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol. 2007;8(2):101-112.
8. Sakono M, Zako T. Amyloid oligomers: formation and toxicity of Abeta oligomers. FEBS J. 2010;277(6):1348-1358.
9. Ferreira ST, Vieira MN, De Felice FG. Soluble protein oligomers as emerging toxins in Alzheimer's and other amyloid diseases. IUBMB Life. 2007;59(4-5):332-345.
10. Sheikh S, Safia, Haque E, Mir SS. Neurodegenerative diseases: multifactorial conformational diseases and their therapeutic interventions. J Neurodegener Dis. 2013; article ID 563481.
11. Yiannopoulou KG, Papageorgiou SG. Current and future treatments for Alzheimer's disease. Ther Adv Neurol Disord. 2013;6(1):19-33.
12. Härd T, Lendel C Inhibition of amyloid formation. J Mol Biol. 2012;421(4-5):441-465.
13. Liu R, Su R, Liang M, et al. Physicochemical strategies for inhibition of amyloid fibril formation: an overview of recent advances. Curr Med Chem. 2011;9(24):4157-4174.
14. Mathis CA, Mason NS, Lopresti BJ, Klunk WE. Development of positron emission tomography β-amyloid plaque imaging agents. Semin Nucl Med. 2012;42(6):423-432.
15. Ono M, Saji H. SPECT Imaging Agents for Detecting Cerebral β-Amyloid Plaques. Int J Mol Imaging. 2011;2011:543267.
16. Wong DF, Rosenberg PB, Zhou Y, et al. In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18). J Nucl Med. 2010;51(6):913-920.
17. Schmidt A, Pahnke J. Efficient near-infrared in vivo imaging of amyoid-β deposits in Alzheimer's disease mouse models. J Alzheimers Dis. 2013;0(3):651-664.
18. Quek CH, Leong KW. Near-infrared fluorescent nanoprobes for in vivo optical imaging. Nanomaterials. 2012;2:92-112.
19. He X, Wang K, Cheng Z. In vivo near-infrared fluorescence imaging of cancer with nanoparticle-based probes. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2010;2(4):349-366.
20. Wu X, Chang S, Sun X, et al. Constructing NIR silica-cyanine hybrid nanocomposite for bioimaging in vivo: a breakthrough in photo-stability and bright fluorescence with large Stokes shift. Chem Sci. 2013;4: 1221-1228.
21. Mahmoudi M, Kalhor HR, Laurent S, Lynch I. Protein fibrillation and nanoparticle interactions: opportunities and challenges. Nanoscale. 2013;5(7):2570-2588.
22. Spuch C, Saida O, Navarro C. Advances in the treatment of neurodegenerative disorders employing nanoparticles. Recent Pat Drug Deliv Formul. 2012;6(1):2-18.
23. Re F, Gregori M, Masserini M. Nanotechnology for neurodegenerative disorders. Maturitas. 2012;73(1):45-51.
24. Sahni JK, Doggui S, Ali J, Baboota S, Dao L, Ramassamy C. Neurotherapeutic applications of nanoparticles in Alzheimer's disease. J Control Release. 2011;152(2):208-231.
25. Cabaleiro-Lago C, Szczepankiewicz O, Linse S. The effect of nanoparticles on amyloid aggregation depends on the protein stability and intrinsic aggregation rate. Langmuir. 2012;28(3):1852-1857.
26. Silva GA. Neuroscience nanotechnology: progress, opportunities and challenges. Nat Rev Neurosci. 2006;7(1):65-74.
27. Kabanov AV, Gendelman HE. Nanomedicine in the diagnosis and therapy of neurodegenerative disorders. Prog Polym Sci. 2007;32(8-9): 1054-1082.
28. Wadghiri YZ, Li J, Wang J, et al. Detection of amyloid plaques targeted by bifunctional USPIO in Alzheimer's disease transgenic mice using magnetic resonance microimaging. PLoS One. 2018(2):e57097.
29. Mahmoudi M, Quinlan-Pluck F, Monopoli MP, et al. Influence of the physiochemical properties of superparamagnetic iron oxide nanoparticles on amyloid β protein fibrillation in solution. ACS Chem Neurosci. 2013;4(3):475-485.
30. Kouyoumdjian H, Zhu DC, El-Dakdouki MH, et al. Glyconanoparticle aided detection of β-amyloid by magnetic resonance imaging and attenuation of β-amyloid induced cytotoxicity. ACS Chem Neurosci. 2013;4(4):575-584.
31. Skaat H, Shafir G, Margel S. Acceleration and inhibition of amyloid-β fibril formation by peptide-conjugated fluorescent-maghemite nanoparticles. J Nanopart Res. 2011;13:3521-3534.
32. Cabaleiro-Lago C, Quinlan-Pluck F, Lynch I, et al. Inhibition of amyloid beta protein fibrillation by polymeric nanoparticles. J Am Chem Soc. 2008;130(46):15437-15443.
33. Cabaleiro-Lago C, Quinlan-Pluck F, Lynch I, Dawson KA, Linse S. Dual effect of amino modified polystyrene nanoparticles on amyloid β protein fibrillation. ACS Chem Neurosci. 2010;1(4): 279-287.
34. Yoo SI, Yang M, Brender JR, et al. Inhibition of amyloid peptide fibrillation by inorganic nanoparticles: functional similarities with proteins. Angew Chem Int Ed Engl. 2011;50(22):5110-5115.
35. Saraiva AM, Cardoso I, Pereira MC, et al. Controlling amyloid-beta peptide(1-42) oligomerization and toxicity by fluorinated nanoparticles. Chembiochem. 2010;11(13):1905-1913.
36. Liao YH, Chang YJ, Yoshiike Y, Chang YC, Chen YR. Negatively charged gold nanoparticles inhibit Alzheimer's amyloid-β fibrillization, induce fibril dissociation, and mitigate neurotoxicity. Small. 2012;8(23): 3631-3639.
37. Saraiva AM, Cardoso I, Saraiva MJ, et al. Randomization of amyloid-β-peptide(1-42) conformation by sulfonated and sulfated nanoparticles reduces aggregation and cytotoxicity. Macromol Biosci. 2010;10(10): 1152-1163.
38. Skaat H, Chen R, Grinberg I, Margel S. Engineered polymer nanoparticles containing hydrophobic dipeptide for inhibition of amyloid-β fibrillation. Biomacromolecules. 2012;13(9):2662-2670.
39. Moreth J, Mavoungou C, Schindowski K. Passive anti-amyloid immunotherapy in Alzheimer's disease: What are the most promising targets? Immun Ageing. 2013;10(1):18.
40. Yu YJ, Watts RJ. Developing therapeutic antibodies for neurodegenerative disease. Neurotherapeutics. 2013;10(3):459-472.
41. Lobello K, Ryan JM, Liu E, Rippon G, Black R. Targeting Beta amyloid: a clinical review of immunotherapeutic approaches in Alzheimer's disease. Int J Alzheimers Dis. 2012;2012:628070.
42. Aisen PS, Vellas B. Passive immunotherapy for Alzheimer's disease: what have we learned, and where are we headed? J Nutr Health Aging. 2013;17(1):49-50.
43. Fu HJ, Liu B, Frost JL, Lemere CA. Amyloid-beta immunotherapy for Alzheimer's disease. CNS Neurol Disord Drug Targets. 2010;9(2): 197-206.
44. Wilcock DM, Colton CA. Anti-amyloid-beta immunotherapy in Alzheimer's disease: relevance of transgenic mouse studies to clinical trials. J Alzheimers Dis. 2008;15(4):555-569.
45. Schenk D, Hagen M, Seubert P. Current progress in beta-amyloid immunotherapy. Curr Opin Immunol. 2004;16(5):599-606.
46. Yamada K, Yabuki C, Seubert P, et al. Abeta immunotherapy: intracerebral sequestration of Abeta by an anti-Abeta monoclonal antibody 266 with high affinity to soluble Abeta. J Neurosci. 2009;29(36):11393-11398.
47. Wilcock DM, DiCarlo G, Henderson D, et al. Intracranially administered anti-Abeta antibodies reduce beta-amyloid deposition by mechanisms both independent of and associated with microglial activation. J Neurosci. 2003;23(9):3745-3751.
48. Spires-Jones TL, Mielke ML, Rozkalne A, et al. Passive immunotherapy rapidly increases structural plasticity in a mouse model of Alzheimer disease. Neurobiol Dis. 2009;33(2):213-220.
49. Kotilinek LA, Bacskai B, Westerman M, et al. Reversible memory loss in a mouse transgenic model of Alzheimer's disease. J Neurosci. 2002;22(15):6331-6335.
50. Jordão JF, Ayala-Grosso CA, Markham K, et al. Antibodies targeted to the brain with image-guided focused ultrasound reduces amyloid-beta plaque load in the TgCRND8 mouse model of Alzheimer's disease. PLoS One. 11, 2010;5(5):e10549.
51. Sakono M, Zako T, Maeda M. Naked-eye detection of amyloid aggregates using gold nanoparticles modified with amyloid beta antibody. Anal Sci. 2012;28(1):73.
52. Cimini A, D'Angelo B, Das S, et al. Antibody-conjugated PEGylated cerium oxide nanoparticles for specific targeting of Aβ aggregates modulate neuronal survival pathways. Acta Biomater. 2012;8(6): 2056-2067.
53. Yang CC, Yang SY, Chieh JJ, et al. Biofunctionalized magnetic nanoparticles for specifically detecting biomarkers of Alzheimer's disease in vitro. ACS Chem Neurosci. 2011;2(9):500-505.
54. Canovi M, Markoutsa E, Lazar AN, et al. The binding affinity of anti-Aβ1-42 MAb-decorated nanoliposomes to Aβ1-42 peptides in vitro and to amyloid deposits in post-mortem tissue. Biomaterials. 2011;32(23): 5489-5497.
55. Sillerud LO, Solberg NO, Chamberlain R, et al. SPION-enhanced magnetic resonance imaging of Alzheimer's disease plaques in AβPP/PS-1 transgenic mouse brain. J Alzheimers Dis. 2013;34(2):349-365.
56. Sigalit Gura, Shlomo Margel, inventors; Bar-Ilan University, assignee. Nucleation and growth of magnetic metaloxide nanoparticles and its use. Israel patent WO 1999062079A1. May 24, 1999.
57. Chen S, Wetzel R. Solubilization and disaggregation of polyglutamine peptides. Protein Sci. 2001;10(4):887-891.
58. Levine H. Thioflavine T interaction with amyloid β-sheet structures. Amyloid. 1995;2:1-6.
59. Bitan G, Lomakin A, Teplow DB. Amyloid beta-protein oligomerization: prenucleation interactions revealed by photo-induced cross-linking of unmodified proteins. J Biol Chem. 2001;276(37):35176-35184.
60. Ziv-Polat O, Topaz M, Brosh T, Margel S. Enhancement of incisional wound healing by thrombin conjugated iron oxide nanoparticles. Biomaterials. 2010;31(4):741-747.
61. Green-Sadan T, Kuttner Y, Lublin-Tennenbaum T, et al. Glial cell line-derived neurotrophic factor-conjugated nanoparticles suppress acquisition of cocaine self-administration in rats. Exp Neurol. 2005;194(1): 97-105.
62. Skaat H, Ziv-Polat O, Shahar A, Margel S. Enhancement of the growth and differentiation of nasal olfactory mucosa cells by the conjugation of growth factors to functional nanoparticles. Bioconjug Chem. 2011;22(12):2600-2610.
63. Shlomo Margel, Benny Perlstein, Chaya Brodie, tom Mikkelsen, inventors; Bar-Ilan University, assignee. Polymer nanoparticles coated by magnetic metal oxide and uses thereof. US patent WO 2009/040811. April 2, 2009.
64. Shafir G, Galperin A, Margel S. Synthesis and characterization of recombinant factor VIIa-conjugated magnetic iron oxide nanoparticles for hemophilia treatment. J Biomed Mater Res A. 2009;91(4): 1056-1064.
65. Corem-Salkmon E, Ram Z, Daniels D, et al. Convection-enhanced delivery of methotrexate-loaded maghemite nanoparticles. Int J Nanomedicine. 2011;6:1595-1602.